Google to Move All Pixel Production Out of China by 2027 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows 
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
REPAY Stock Rises After Visa Platform Connect Collaboration 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Add as a preferred source on Google
South Korean biotech company Celltrion Inc. plans to merge with its two affiliates, Celltrion Healthcare Co. and Celltrion Pharma Inc., to establish a holding company structure by the end of 2021.
Celltrion Group Chairman Seo Jung-jin would establish Celltrion Healthcare Holdings by investing his stakes in Celltrion Healthcare, making the holding company its largest shareholder.
Celltrion Group Chairman Seo Jung-Jin would hold 11.21 percent in Celltrion Healthcare Holdings, which in turn would have a 24.33 percent stake.
The process would be hastened when requirements for relevant laws regarding anti-monopoly and fair trade are met.
Seo noted that the merger would depend upon the wishes of shareholders.
Celltrion is conducting phase one clinical trials on patients of its coronavirus treatment, CT-P59, to evaluate the safety and efficacy of the treatment.
